

# Karl B Lemström

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/919017/karl-b-lemstrom-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

2,202

citations

27

h-index

44

g-index

115

ext. papers

2,395

ext. citations

4.3

avg, IF

3.95

L-index

#	Paper	IF	Citations
88	Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis. <i>American Journal of Pathology</i> , <b>2021</b> ,	5.8	1
87	Plasma proteome of brain-dead organ donors predicts heart transplant outcome.. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> ,	5.8	1
86	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , <b>2020</b> , 34, e13984	3.8	7
85	Cost-utility of venoarterial extracorporeal membrane oxygenation in cardiogenic shock and cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 9, 333-341	4.3	3
84	Hypoxia-inducible factor controls immunoregulatory properties of myeloid cells in mouse cardiac allografts - an experimental study. <i>Transplant International</i> , <b>2019</b> , 32, 95-106	3	5
83	Donor Simvastatin Treatment in Heart Transplantation. <i>Circulation</i> , <b>2019</b> , 140, 627-640	16.7	13
82	Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2019</b> , 55, 780-787	3	8
81	Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion. <i>Transplant Immunology</i> , <b>2016</b> , 37, 40-45	1.7	15
80	Platelet-derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury. <i>Transplantation</i> , <b>2016</b> , 100, 303-13	1.8	7
79	Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 1160-72	8.7	21
78	Increased myeloid cell hypoxia-inducible factor-1 delays obliterative airway disease in the mouse. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 671-8	5.8	2
77	Simvastatin Treatment Upregulates Anti-Fibrotic Bone Morphogenetic Protein-7 Expression at Rat Cardiac Allograft Rejection. <i>Pharmacology</i> , <b>2016</b> , 98, 204-208	2.3	1
76	VEGF Pathways in the Lymphatics of Healthy and Diseased Heart. <i>Microcirculation</i> , <b>2016</b> , 23, 5-14	2.9	27
75	Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts. <i>American Journal of Transplantation</i> , <b>2015</b> , 15, 2075-84	8.7	15
74	Systemic overexpression of matricellular protein CCN1 exacerbates obliterative bronchiolitis in mouse tracheal allografts. <i>Transplant International</i> , <b>2015</b> , 28, 1416-25	3	6
73	Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 1096-108	8.7	24
72	Transgenic Overexpression of Cardiac-Specific Vascular Endothelial Growth Factor B Exacerbates Ischemia Reperfusion Injury in Rat Cardiac Grafts.. <i>Transplantation</i> , <b>2014</b> , 98, 352-353	1.8	

71	Three decades of heart transplantation in Scandinavia: long-term follow-up. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 308-15	12.3	27
70	Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. <i>Transplant International</i> , <b>2013</b> , 26, 1126-37	3	7
69	Donor simvastatin treatment and cardiac allograft ischemia/reperfusion injury. <i>Trends in Cardiovascular Medicine</i> , <b>2013</b> , 23, 85-90	6.9	6
68	VEGF Receptor Signaling in the Cardiac Lymphatics <b>2013</b> , 125-143		1
67	Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 2019-34	8.7	33
66	Differential effects of pharmacological HIF preconditioning of donors versus recipients in rat cardiac allografts. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 600-10	8.7	12
65	Combined donor simvastatin and methylprednisolone treatment prevents ischemia-reperfusion injury in rat cardiac allografts through vasculoprotection and immunomodulation. <i>Transplantation</i> , <b>2013</b> , 95, 1084-91	1.8	9
64	Effect of simvastatin on development of obliterative airway disease: an experimental study. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 194-203	5.8	4
63	Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. <i>American Journal of Pathology</i> , <b>2012</b> , 181, 1607-20	5.8	35
62	Usefulness of extracorporeal membrane oxygenation as a bridge to lung transplantation: a descriptive study. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 103-7	5.8	100
61	Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 707-16	5.8	9
60	Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. <i>Circulation</i> , <b>2011</b> , 124, 1138-50	16.7	58
59	Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. <i>Circulation</i> , <b>2010</b> , 121, 1413-22	16.7	105
58	Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. <i>Circulation</i> , <b>2010</b> , 122, 1725-33	16.7	113
57	Natural course and risk factors for impaired renal function during the first year after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 633-40	5.8	27
56	Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1047-57	5.8	26
55	Cardiomyocyte-targeted HIF-1alpha gene therapy inhibits cardiomyocyte apoptosis and cardiac allograft vasculopathy in the rat. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1058-66	5.8	11
54	Association between gastrointestinal symptoms and health-related quality of life after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1388-94	5.8	12

53	Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 4459-64	1.1	19
52	PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 691-8	9.4	38
51	Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. <i>Journal of Heart and Lung Transplantation</i> , <b>2008</b> , 27, 856-64	5.8	19
50	Vascular endothelial growth factor in chronic rat allograft nephropathy. <i>Transplant Immunology</i> , <b>2008</b> , 19, 136-44	1.7	18
49	VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 819-25	9.4	19
48	Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 174, 1145-52	10.2	28
47	Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and -2 expression in rat cardiac allograft vasculopathy. <i>Circulation Research</i> , <b>2006</b> , 98, 1373-80	15.7	32
46	Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts. <i>Journal of Heart and Lung Transplantation</i> , <b>2006</b> , 25, 569-78	5.8	4
45	The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis. <i>Transplantation Proceedings</i> , <b>2006</b> , 38, 3271-3	1.1	13
44	Effect of graft preservation and acute rejection on hypoxia-inducible factor-1 in rat cardiac allografts. <i>Transplantation Proceedings</i> , <b>2006</b> , 38, 3372-3	1.1	3
43	Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. <i>Transplantation Proceedings</i> , <b>2006</b> , 38, 3266-7	1.1	7
42	Angiogenic growth factors in cardiac allograft rejection. <i>Transplantation</i> , <b>2006</b> , 82, S22-4	1.8	1
41	Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 1421-9	10.2	37
40	Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. <i>Transplantation</i> , <b>2005</b> , 79, 182-9	1.8	31
39	A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients. <i>Transplant International</i> , <b>2005</b> , 18, 1318-27	3	4
38	Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 713-20	8.7	17
37	Role of angiogenic growth factors in transplant coronary artery disease. <i>Annals of Medicine</i> , <b>2004</b> , 36, 184-93	1.5	11
36	Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts. <i>Transplantation</i> , <b>2004</b> , 77, 655-8	1.8	7

35	Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. <i>Transplantation</i> , <b>2003</b> , 75, 334-9	1.8	18
34	Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. <i>Circulation</i> , <b>2003</b> , 107, 1308-14	16.7	85
33	Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. <i>Circulation</i> , <b>2002</b> , 105, 2524-30	16.7	116
32	Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 724-9	10.2	39
31	Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 710-7	15.1	10
30	Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart-lung allograft recipients. <i>Clinical Transplantation</i> , <b>2001</b> , 15, 77-88	3.8	30
29	PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 318	1.1	5
28	Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 1801	1.1	7
27	Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty. <i>FASEB Journal</i> , <b>1999</b> , 13, 387-94	0.9	40
26	Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. <i>Circulation</i> , <b>1999</b> , 99, 2295-301	16.7	60
25	Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. <i>Cardiovascular Drugs and Therapy</i> , <b>1999</b> , 13, 159-68	3.9	61
24	Enhanced intimal proliferation upon injury to pre-existing neointima and resistance of neointimal cells to cell death. <i>Cardiovascular Pathology</i> , <b>1999</b> , 8, 339-47	3.8	9
23	Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. <i>Transplantation Proceedings</i> , <b>1999</b> , 31, 102	1.1	5
22	Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and CMV infection in lung and heart-lung allograft recipients. <i>Transplantation Proceedings</i> , <b>1999</b> , 31, 163-4	1.1	8
21	Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor. <i>Transplantation Proceedings</i> , <b>1999</b> , 31, 187	1.1	8
20	Inhibition of complement reduces obliterative bronchiolitis. <i>Transplantation Proceedings</i> , <b>1999</b> , 31, 188	1.1	5
19	CMV infection and allograft rejection. <i>Transplantation Proceedings</i> , <b>1998</b> , 30, 916-7	1.1	12
18	Immunobiology and pathology of chronic rejection. <i>Transplantation Proceedings</i> , <b>1997</b> , 29, 77-8	1.1	15

17	Cytomegalovirus infection accelerates experimental obliterative bronchiolitis via platelet-derived growth factor upregulation. <i>Transplantation Proceedings</i> , <b>1997</b> , 29, 798	1.1	3
16	Expression of platelet-derived growth factor in the development of cardiac allograft vasculopathy in the rat. <i>Transplantation Proceedings</i> , <b>1997</b> , 29, 1045-6	1.1	11
15	Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. <i>Circulation</i> , <b>1997</b> , 95, 2614-6	16.7	48
14	Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. <i>Kidney International</i> , <b>1996</b> , 50, 526-37	9.9	62
13	Cytomegalovirus infection accelerates obliterative bronchiolitis of rat tracheal allografts. <i>Transplant International</i> , <b>1996</b> , 9 Suppl 1, S221-2	3	1
12	De novo expression of endothelial sialyl Lewis(a) and sialyl Lewis(x) during cardiac transplant rejection: superior capacity of a tetravalent sialyl Lewis(x) oligosaccharide in inhibiting L-selectin-dependent lymphocyte adhesion. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 182, 1133-41	16.6	92
11	Induction of adhesion molecules on the endothelia of rejecting cardiac allografts. <i>Journal of Heart and Lung Transplantation</i> , <b>1995</b> , 14, 205-13	5.8	15
10	Cytomegalovirus infection accelerates mRNA expression of several smooth muscle cell growth factors in the allograft vascular wall. <i>Transplantation Proceedings</i> , <b>1995</b> , 27, 566-7	1.1	6
9	Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. <i>Circulation</i> , <b>1995</b> , 92, 2594-604	16.7	68
8	Molecular mechanisms of chronic renal allograft rejection. <i>Kidney International, Supplement</i> , <b>1995</b> , 52, S2-10		4
7	Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. <i>Transplant International</i> , <b>1994</b> , 7 Suppl 1, S363-4	3	6
6	Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMP. <i>Transplant International</i> , <b>1994</b> , 7 Suppl 1, S365-70	3	29
5	Frequency of infections and their relation to episodes of acute rejection among heart allograft recipients. <i>Presse Medicale</i> , <b>1994</b> , 23, 1252-6	2.2	3
4	Triple-drug immunosuppression significantly reduces chronic rejection in noninfected and RCMV-infected rats. <i>Transplantation Proceedings</i> , <b>1994</b> , 26, 1727-8	1.1	4
3	Chronic allograft rejection. <i>Immunological Reviews</i> , <b>1993</b> , 134, 33-81	11.3	207
2	Cytomegalovirus infection enhances allograft arteriosclerosis in the rat. <i>Transplantation Proceedings</i> , <b>1993</b> , 25, 1406-7	1.1	10
1	Towards understanding the pathophysiology of chronic rejection. <i>The Clinical Investigator</i> , <b>1992</b> , 70, 780-90		39